Medical costs and healthcare resource use in patients with lupus nephritis and neuropsychiatric lupus in an insured population

Fürst, Daniel E.; Clarke, Ann E.; Fernandes, Ancilla W.; Bancroft, T. A.; Gajria, Kavita; Greth, Warren; Iorga, Şerban R.

doi:10.3111/13696998.2013.772058

Cited by 27 publications

(70 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Studies from the US have shown that patients with LN incurred annual costs that are 2.5 to 6-fold higher than patients without LN (1,12–14). Carls et al reported annual costs were almost 4-fold higher in US patients with LN [$83 869 versus $ 22 188 in those without LN]1 (1) while Furst et al .…”

Section: Discussionmentioning

confidence: 99%

“…Carls et al reported annual costs were almost 4-fold higher in US patients with LN [$83 869 versus $ 22 188 in those without LN]1 (1) while Furst et al . reported that patients with LN incurred annual costs of $44 524 versus $7113 in matched controls without SLE (14). A Medicaid study reported lower annual costs, but the differential between those with LN and matched controls without SLE was almost 3-fold [$38 401 versus $12 945] (12).…”

Section: Discussionmentioning

confidence: 99%

“…The presence of renal damage is the most important predictor of early mortality in SLE patients (9); in fact, it has been shown that renal damage reduces the survival of SLE patients by approximately 24 years, compared to the general population (10), and LN patients who develop ESRD have a 26-fold increased risk of mortality (11). Hence, numerous studies demonstrate significantly higher costs in patients with LN versus those without LN (1,(12)(13)(14).…”

Section: Introductionmentioning

confidence: 99%

“…com/doi/10.1002/acr.23480/abstract), and because of our study design, we have no data on resource use in the year preceding death.The substantial cost of LN has been reported by others, primarily through the use of insurance claims databases. Studies from the US have shown that patients with LN incurred annual costs that are 2.5-to 6-fold higher than patients without LN(1,(12)(13)(14). Carls et al reported that annual costs were almost 4-fold higher in US patients with LN ($83,869 versus $22,188 in those without LN) (1) while Furst et al reported that patients with LN incurred annual costs of $44,524 versus $7,113 in matched controls without SLE(14).…”

mentioning

confidence: 99%

“…Studies from the US have shown that patients with LN incurred annual costs that are 2.5-to 6-fold higher than patients without LN(1,(12)(13)(14). Carls et al reported that annual costs were almost 4-fold higher in US patients with LN ($83,869 versus $22,188 in those without LN) (1) while Furst et al reported that patients with LN incurred annual costs of $44,524 versus $7,113 in matched controls without SLE(14). (Note that currencies from publications have been converted to 2015 Canadian dollars using purchasing power parities data from the Organisation for Economic Cooperation and Development [https://data.oecd.org/conversion/ purchasing-power-parities-ppp.htm] and the consumer price index from Statistics Canada [http://www.statcan.gc.ca/ tables-tableaux/sum-som/l01/cst01/econ09a-eng.htm]).…”

mentioning

confidence: 99%

See 4 more Smart Citations

Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach

Barber

Hanly

et al. 2018

Arthritis Care & Research

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach

Barber

Hanly

et al. 2018

Arthritis Care & Research

View full text Add to dashboard Cite

show abstract

Assessing the Costs of Neuropsychiatric Disease in the Systemic Lupus International Collaborating Clinics Cohort Using Multistate Modeling

Clarke

Hanly

Urowitz

et al. 2023

Arthritis Care & Research

View full text Add to dashboard Cite

ObjectiveTo estimate direct and indirect costs associated with neuropsychiatric (NP) events in the Systemic Lupus International Collaborating Clinics inception cohort.MethodsNP events were documented annually using American College of Rheumatology definitions for NP events and attributed to systemic lupus erythematosus (SLE) or non‐SLE causes. Patients were stratified into 1 of 3 NP states (no, resolved, or new/ongoing NP event). Change in NP status was characterized by interstate transition rates using multistate modeling. Annual direct costs and indirect costs were based on health care use and impaired productivity over the preceding year. Annual costs associated with NP states and NP events were calculated by averaging all observations in each state and adjusted through random‐effects regressions. Five‐ and 10‐year costs for NP states were predicted by multiplying adjusted annual costs per state by expected state duration, forecasted using multistate modeling.ResultsA total of 1,697 patients (49% White race/ethnicity) were followed for a mean of 9.6 years. NP events (n = 1,971) occurred in 956 patients, 32% attributed to SLE. For SLE and non‐SLE NP events, predicted annual, 5‐, and 10‐year direct costs and indirect costs were higher in new/ongoing versus no events. Direct costs were 1.5‐fold higher and indirect costs 1.3‐fold higher in new/ongoing versus no events. Indirect costs exceeded direct costs 3.0 to 5.2 fold. Among frequent SLE NP events, new/ongoing seizure disorder and cerebrovascular disease accounted for the largest increases in annual direct costs. For non‐SLE NP events, new/ongoing polyneuropathy accounted for the largest increase in annual direct costs, and new/ongoing headache and mood disorder for the largest increases in indirect costs.ConclusionPatients with new/ongoing SLE or non‐SLE NP events incurred higher direct and indirect costs.

show abstract

Medical costs incurred by organ damage caused by active disease, comorbidities and side effect of treatments in systemic lupus erythematosus patients: a Taiwan nationwide population-based study

2016

View full text Add to dashboard Cite

This study aims to systematically investigate the medial expenditures incurred by systemic lupus erythematosus (SLE)-associated organ damages in order to assess the economic impact of damage accrual by active disease, comorbidities and side effect of treatments. In total, 22,258 SLE cases were identified from the National Health Insurance Research Database, and organ damages assessed were according to the list from Systemic Lupus International Collaborative Clinic/American Rheumatology damage index system. Medical expenditures incurred by organ damages in the first as well as the subsequent year were obtained from the database. Our data reflected that organ damages caused by active disease and comorbidities, such those of renal, neuropsychiatric, pulmonary and cardiovascular systems are among the highest costing of all damage items. This study also shows that significant medical expenditures are incurred by damage items such as those occurring in ocular and musculoskeletal systems, which are typically caused by side effect of treatments such as corticosteroids. The medical expenditure in subsequent year still causes substantial economic burden. This systematic and continuous survey provided important reference of disease burden of SLE.

show abstract

Medical costs and healthcare resource use in patients with lupus nephritis and neuropsychiatric lupus in an insured population

Abstract: Subjects with lupus nephritis or NPSLE have high costs and resource use, compared to unaffected controls.

Cited by 27 publications

References 19 publications

Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach

Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach

Assessing the Costs of Neuropsychiatric Disease in the Systemic Lupus International Collaborating Clinics Cohort Using Multistate Modeling

Medical costs incurred by organ damage caused by active disease, comorbidities and side effect of treatments in systemic lupus erythematosus patients: a Taiwan nationwide population-based study

Contact Info

Product

Resources

About